文献速递肝病消化道肿瘤与早癌

1110例肝细胞癌患者临床表现与预后的性别差异

Sex disparities in presentation and prognosis of 1110 patients with hepatocellular carcinoma.
PubMed 文献 · Aliment Pharmacol Ther · 2020-06-29

该回顾性研究纳入2008至2017年两家美国医疗系统连续诊断的1110例肝细胞癌患者(女性23.5%),分析性别与临床表现及预后的关系。女性诊断时年龄更大、早期肿瘤比例更高,校正混杂因素后女性性别与更低死亡风险、早期肿瘤检出及一线治疗反应独立相关。

要点

  • 女性肝细胞癌诊断时年龄更大(平均62.5 vs 59.2岁,P<0.001),早期BCLC 0/A期比例更高(53.1% vs 43.7%,P=0.04)。
  • 单因素分析女性总生存优于男性(中位17.1 vs 12.0个月,P=0.02),<65岁女性生存优于男性(18.3 vs 11.2个月,P=0.02)。
  • 多因素校正后女性性别与更低死亡风险独立相关(HR 0.82,95%CI 0.68-0.98)。

核心结论

  • 在大型肝细胞癌队列中,女性预后显著优于男性。

研究设计与样本

  • 回顾性研究,纳入2008至2017年两家美国医疗系统连续诊断的肝细胞癌患者1110例,女性占23.5%。
  • 采用Cox比例风险模型和多因素logistic回归分析总生存、早期肿瘤检出及治疗反应(依据mRECIST标准)。

主要发现

  • 女性诊断时年龄更大(平均62.5 vs 59.2岁,P<0.001),早期BCLC 0/A期比例更高(53.1% vs 43.7%,P=0.04),肝功能相似(Child Pugh A级49.2% vs 47.1%,P=0.27)。
  • 单因素分析女性总生存优于男性(中位17.1 vs 12.0个月,P=0.02)。
  • 按年龄分层,<65岁女性总生存优于男性(18.3 vs 11.2个月,P=0.02);≥65岁女性与男性总生存相似(15.5 vs 15.7个月,P=0.45)。
  • 多因素校正年龄、种族/民族、甲胎蛋白、BCLC分期、ALBI分级和Child Pugh评分后,女性性别与更低死亡风险独立相关(HR 0.82,95%CI 0.68-0.98)。
  • 次要分析中,校正相同协变量后,女性性别与早期肿瘤检出(OR 1.46,95%CI 1.05-2.02)及一线肝细胞癌治疗反应(OR 1.72,95%CI 1.18-2.53)独立相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although sex disparities in hepatocellular carcinoma (HCC) incidence have been well described, there are limited data examining sex disparities in HCC prognosis. AIM: To characterise sex differences in HCC presentation and prognosis. METHODS: We performed a retrospective study of consecutive patients (n = 1110, 23.5% women) diagnosed with HCC between 2008 and 2017 at two US health systems. We used Cox proportional hazard and multivariable logistic regression models to identify factors associated with overall survival, early tumour detection and response to HCC treatment (per the modified Response Evaluation Criteria in Solid Tumors [mRECIST] criteria). RESULTS: Women were older at HCC diagnosis (mean 62.5 vs 59.2 years, P < 0.001) and had a higher proportion of early-stage tumours (53.1% vs 43.7% Barcelona Clinic Liver Cancer [BCLC] stage 0/A, P = 0.04), but similar liver function compared to men (49.2% vs 47.1% Child Pugh A, P = 0.27). In univariable analysis, women had significantly better overall survival than men (median 17.1 vs 12.0 months, P = 0.02). When stratified by age, younger (<65 years) women had better overall survival than men (18.3 vs 11.2 months, P = 0.02); however, older (≥65 years) women and men had similar overall survival (15.5 vs 15.7 months, P = 0.45). In multivariable analysis, female sex was independently associated with lower mortality after adjusting for age, race/ethnicity, alpha-fetoprotein, BCLC stage, Albumin-Bilirubin grade and Child Pugh score (hazard ratio [HR] 0.82, 95% confidence interval [CI] 0.68-0.98). In secondary analyses, female sex was independently associated with early tumour detection (odds ratio [OR] 1.46, 95% CI 1.05-2.02) and response to first HCC treatment (OR 1.72, 95% CI 1.18-2.53) after adjusting for the same covariates. CONCLUSION: In a large cohort of patients with HCC, women had significantly better prognosis than men.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Rich NE, Murphy CC, Yopp AC, et al. Sex disparities in presentation and prognosis of 1110 patients with hepatocellular carcinoma. Aliment Pharmacol Ther. 2020. PMID: 32598091. doi:10.1111/apt.15917

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。